New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis [...]
Genzyme Introduces vs.MS, a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better Informed [...]
Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large [...]
Intended for U.S. Media Only Whippany, N.J., September 25, 2015 – Bayer HealthCare announced today that the U.S. Food and Drug [...]
Novartis acquires all remaining rights to GSK’s Ofatumumab to develop treatments for MS and other autoimmune indications Novartis [...]
EMD Serono and Opexa amend agreement to support ongoing development of Tcelna for multiple sclerosis
EMD Serono and Opexa Amend Agreement to Support Ongoing Development of Tcelna (imilecleucel-T) for Multiple Sclerosis Personalized [...]
Multiple Sclerosis Coalition Applauds Passage of 21st Century Cures Act Inclusion of data-gathering provision is vital to future MS [...]
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase [...]
Multiple Sclerosis Coalition Announces New Board President Lisa Taylor Skutnik elected to lead coalition of MS nonprofits Cherry [...]
Sandoz announces US launch of Glatopa™, the first generic competitor to Copaxone® 20mg Glatopa is the first FDA-approved, [...]